UK markets close in 1 hour 13 minutes
  • FTSE 100

    7,553.08
    -14.46 (-0.19%)
     
  • FTSE 250

    19,177.15
    -152.43 (-0.79%)
     
  • AIM

    840.07
    -10.65 (-1.25%)
     
  • GBP/EUR

    1.1589
    -0.0026 (-0.22%)
     
  • GBP/USD

    1.2161
    -0.0033 (-0.27%)
     
  • BTC-GBP

    13,955.28
    -158.82 (-1.13%)
     
  • CMC Crypto 200

    399.81
    -1.99 (-0.50%)
     
  • S&P 500

    3,964.02
    -34.82 (-0.87%)
     
  • DOW

    33,791.62
    -155.48 (-0.46%)
     
  • CRUDE OIL

    76.34
    -0.59 (-0.77%)
     
  • GOLD FUTURES

    1,783.90
    +2.60 (+0.15%)
     
  • NIKKEI 225

    27,885.87
    +65.47 (+0.24%)
     
  • HANG SENG

    19,441.18
    -77.11 (-0.40%)
     
  • DAX

    14,354.30
    -93.31 (-0.65%)
     
  • CAC 40

    6,679.73
    -17.23 (-0.26%)
     

Could This Unknown Stock Beat Moderna in 2023?

Vaxart (NASDAQ: VXRT) might just be gearing up to steal coronavirus vaccine market share from Moderna (NASDAQ: MRNA) in the next couple of years, making its investors wealthy in the process. The biotech's vaccine tablets could have a few advantages that Moderna's shots don't, including one in particular, that might be a public health holy grail at the moment. For Vaxart's stock to beat Moderna's next year, two things need to happen.